Keywords: UK, Pharmaceutical industry, Economic and political pressure, NICE
UK pharma industry beset by economic and political pressures
Article | 3 November 2009
The UK improved its position by one place, and is now ranked fifth of the nine Western European markets surveyed in Business Monitor International's Business Environment Ratings (BER) for the fourth quarter of 2009.
However, while the UK is one of the most developed pharmaceutical markets in the world, pressing economic and political issues, as well as its strict pricing and reimbursement regimes and the upcoming patent cliff - are conspiring to reduce the market's rate of development in the coming years. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
